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Abstract The UV-visible results of this kinetic study show that
amphothericin B as Fungizone is a much stronger oxidant than
CuSO4, itself a powerful oxidant of low-density lipoprotein
(LDL). Amphotericin B as AmBisome alone has no oxidizing
effect on LDL while a mixture of both AmBisome and CuSO4
induces an important potentialization of the LDL oxidation.
These results allow us to believe that the high toxicity of
amphotericin B is related to its capacity to modify and to weaken
the structure of LDL. In addition, differential scanning
calorimetry experiments show that the oxidative modifications
of LDL by CuSO4 or by amphotericin B proceed through
different mechanisms.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Amphotericin B (AmB), usually administered as Fungizone,
a preparation using sodium deoxycholate, is the most power-
ful and e¡ective antifungal drug used in the treatment of
mycotic infections, but with a number of adverse e¡ects, in-
cluding myocardial toxicity [1].
Recent studies from our laboratory have established that
the AmB species responsible, at least in part, for the in vivo
toxicity, is a complex of the antibiotic with the low-density
(LDL) and very-low-density lipoproteins. We have shown that
hindering of this complex formation results in a decrease of
the AmB toxicity [2], results con¢rmed by others [3]. In fact,
Barwicz et al. [4] have shown that Fungizone strongly modi-
¢ed the LDL structure and enhanced the formation of lipid
oxidation products. On the contrary, AmBisome, a less toxic
liposomal formulation of AmB did not a¡ect LDL oxidation
[4]. If one takes into account that products of LDL oxidation
are highly toxic [5^7] one can hypothesize that if AmB enhan-
ces this process, the AmB-lipoprotein interaction may, at least
in part, be directly responsible for some of the toxic side-
e¡ects of the drug.
In this context, in order to get information on the induction
of oxidation products of LDL by AmB, we have compared
the kinetics of copper-induced oxidation of LDL with that
induced by Fungizone or AmBisome, one of the techniques
used being UV-vis spectroscopy. Our results show that Fun-
gizone is a much stronger oxidant than CuSO4, a powerful
oxidant of lipoproteins. AmBisome alone has no oxidizing
e¡ect on LDL while a mixture of both AmBisome and CuSO4
shows an important potentialization of the oxidation of the
lipid part of LDL. On the other hand, the di¡erential scan-
ning calorimetry (DSC) thermograms are consistent with our
¢ndings that the oxidative modi¢cation of LDL by CuSO4 or
by AmB proceed through di¡erent mechanisms.
2. Materials and methods
2.1. Chemicals
Amphotericin B as Fungizone was obtained from Squibb, Canada.
AmBisome was a generous gift of Vestar, CA, USA. The others
chemicals were from usual sources and were used without further
puri¢cation.
2.2. Lipoprotein preparation
Lipoprotein fractions were separated from fresh human plasma
obtained from two healthy volunteers, by sequential preparative ultra-
centrifugation at 18‡C, as described by Hatch and Lees [8]. The den-
sity-range-delivered LDL was 1.006^1.063 g/ml. The isolated LDL
were dialyzed against 1.5 mM phosphate-bu¡ered saline (PBS) con-
taining no EDTA and sterilized with a porous ¢lter (0.22 Wm). The
LDL solution obtained in this step was used as a stock solution and
was stored at 7‡C for no more than 20 days. The concentration of
LDL was determined by the Lowry-Markwel method using bovine
serum albumin as a standard. Cholesterol level was measured by
enzymatic method and remained stable during 20 days. In all experi-
ments the concentration of lipoprotein was 200 Wg of protein/ml.
2.3. Preparation of the solutions
All the solutions (PBS, CuSO4, Fungizone and AmBisome) were
prepared in demineralized and double distilled water. The stock so-
lution of AmB (0.26 mM) as Fungizone or AmBisome was always
prepared immediately before use. The stock solution of CuSO4 was
0.1 mM. For the UV-vis studies the ¢nal concentrations of AmB,
CuSO4 and LDL were 26 WM, 10 WM and 200 Wg of protein/ml,
respectively, using 1.5 mM PBS to obtain the desired volume. In order
to record a su⁄cient signal, the concentrations used in the DSC ex-
periments were 20 times larger.
2.4. UV-vis spectroscopy
The absorbance values and the absorption spectra were recorded
using a Milton Roy Spectronic 3000 array spectrophotometer. For the
kinetic experiments (which were run at 37‡C during 24 h) the refer-
ence and sample cells were placed in a thermo-electric cuvette holder
with a temperature stability of þ 0.05‡C, a probe directly monitored
the temperature of the sample solution with þ 0.3‡C accuracy. The
absorbance was recorded at 234 nm and at 680 nm every 3 min for the
¢rst 3 h and at longer intervals of time after that. Complete spectra
were recorded a few times during the kinetic experiment.
2.5. Di¡erential scanning calorimetry
The thermograms were recorded on a Hart Scienti¢c Di¡erential
Scanning Calorimeter (Calorimetry Sciences, Provo, UT, USA) from
10 to 60‡C at a scan rate of 10‡C/h. The thermogram of the bu¡er
used is subtracted from the thermogram obtained and then corrected
for the thermal delay of the calorimeter.
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All the experimental results were repeated from three to seven times
and were reproducible. The ¢gures show the results of a representative
experiment.
3. Results and discussion
It has been shown previously that a direct relationship was
found between the interaction of AmB with LDL or VLDL
and the in vivo toxicity of this drug [2,3]. It was demonstrated
that LDL had a strong a⁄nity to the aggregated form of
AmB and that this interaction caused an oxidative modi¢ca-
tion of the lipoprotein. This oxidative reaction might be at-
tributed to the well known property of AmB to form radicals
of great chemical reactivity [9]. UV-vis spectroscopy has been
used previously in the literature to determine the susceptibility
of LDL to in vitro oxidation, particularly by monitoring the
increase of absorbance at 234 nm [10^12]. At this wavelength
the conjugated dienes resulting from phospholipid oxidation
[10], as well as the oxidized cholesterol [11] absorb. In many
recent studies a solution of CuSO4 was used as a model sys-
tem to monitor the physiological oxidation of the lipoprotein
(e.g. [13,14]).
In the present study, we have compared the kinetics of
copper-induced LDL oxidation with the oxidation induced
by Fungizone or AmBisome alone. In addition, we have
also studied the e¡ect of a mixture of AmB (as Fungizone
or AmBisome) together with CuSO4 on the formation of
LDL oxidation products. The changes in the UV-vis spectra
of AmB during a 24 h incubation time at 37‡C, were also
monitored. Some of these spectra are presented in Fig. 1. In
this ¢gure the spectra of AmB (as Fungizone or as AmBi-
some) alone or in the presence of LDL, CuSO4 or LDL and
CuSO4, are shown. Fig. 1A presents the spectra of AmB alone
(as Fungizone) or in mixture with CuSO4. The two series of
spectra are identical, thereby showing that CuSO4 does not
a¡ect the spectrum of the drug. The results showed, however,
that a decrease in the absorption at 328 nm occurred during
the incubation time. This indicates that a degradation of
AmB, probably due to autoxidation, occurred, a well known
phenomenon for AmB [9]. On the other hand, the spectra did
not show modi¢cations in the light scattering pattern (the
absorbances at 300 nm or at 450 nm remained the same
over 24 h), indicating that clusters of AmB are not formed
as a function of time. In the presence of LDL the spectrum of
AmB (as Fungizone) is di¡erent (Fig. 1B) and present the
typical characteristics of a spectrum of AmB in interaction
with cholesterol [2]. The spectral changes observed during
the 24 h incubation indicate a decrease of this interaction
(Fig. 1B, arrows) and a small increase in the light scattering
Fig. 1. Spectra of AmB, as Fungizone or AmBisome, in studied
systems. A: Spectra of AmB (as Fungizone) alone or in mixture
with CuSO4. The arrow indicates a decrease of the absorption at
328 nm during a 24 h incubation at 37‡C (1) 10 min; (2) 175 min;
(3) 345 min; (4) 1440 min, i.e. 24 h, of incubation. B: Spectra of
AmB as Fungizone in the presence of LDL. Arrows indicate the
spectral changes during 24 h incubation at 37‡C (1) 10 min;
(2) 43 min; (3) 115 min; (4) 500 min; (5) 1440 min, i.e. 24 h of
incubation. C: Spectra of AmB (as AmBisome) alone or in the
presence of CuSO4, LDL or CuSO4+LDL, monitored during 24 h
incubation at 37‡C.
Fig. 2. Changes of the absorbance at 234 nm as a function of time
to study the kinetics of the oxidative e¡ect on LDL as a function
of the various additives.
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pattern. It is interesting to note that these changes started
immediately after the addition of Fungizone to the LDL so-
lution (compare spectrum 1 of Fig. 1A and B). Strikingly
di¡erent results are observed when AmBisome is used instead
of Fungizone. In this case, Fig. 1C shows that the spectra of
AmB (as AmBisome) either alone, or in the presence of
CuSO4, or in the presence of LDL, or both CuSO4 and
LDL are identical and do not change during the 24 h incu-
bation time at 37‡C.
A comparison of the kinetics results obtained for all the
systems under study is presented in Fig. 2 which shows the
absorbance recorded at 234 nm plotted as a function of time.
The results presented in this ¢gure illustrate the net oxidative
e¡ect of the various additives on LDL because the solution of
the lipoprotein alone, incubated under the same conditions as
the samples under study, was placed in the reference cell.
Therefore, the absorbance at 234 nm was automatically cor-
rected for the natural autoxidation of LDL. In addition, Fun-
gizone or AmBisome alone present a small absorption at this
wavelength. However, it is important to note that this absorp-
tion is not changing either during the 24 h incubation time or
when CuSO4 is present in solution. The absorbance at 234 nm
was thus also corrected for that absorption. In this context, it
is observed that under the same conditions (24 h incubation at
37‡C), AmB as Fungizone is a much stronger oxidant of LDL
than CuSO4. On the other hand, AmB as AmBisome seems to
protect the lipoproteins against an oxidative process, espe-
cially during the ¢rst 4 h. In addition, since in the human
body some oxidants may be present, it was interesting to
study also the oxidative action of a mixture of Fungizone
and CuSO4 on LDL. In this case, the curve increases progres-
sively during 24 h reaching an absorbance level at 234 nm
twice that of the Fungizone+LDL sample. The situation is
completely di¡erent when LDL is put in the presence of
both AmBisome and CuSO4. Here, a striking e¡ect is ob-
served: the oxidation of LDL caused by liposomal AmB (Am-
Bisome) with CuSO4 is more than seven times higher than the
one caused by CuSO4 alone. One may think that the impor-
tant increase of the signal observed with AmBisome in the
presence of CuSO4 might be due to an aggregation of the
small vesicles of AmBisome, thus leading to an increase of
the light scattering. However, this is not the case since the
absorbance at 234 nm does not change at all when CuSO4
is put in presence of AmBisome alone during the whole in-
cubation time.
It is thus very surprising that despite the fact that AmBi-
some alone has no oxidizing e¡ect on LDL and despite the
fact that CuSO4 has also by itself no e¡ect on AmBisome
(Fig. 1C), a mixture of both AmBisome and CuSO4 shows
such an important potentialization of the LDL oxidation. It
may thus be suggested that the low-toxic formulation of AmB
(AmBisome), might become a powerful oxidant if oxidative
conditions, such as in atherosclerotic lesions for example, are
already present.
Our results therefore show that a delicate redox equilibrium
is created under the present experimental conditions, owing to
the characteristics of the components used here. The main
elements of this equilibrium are: the facility of AmB for au-
toxidation, the great susceptibility of LDL to oxidation,
mainly in the presence of free radicals, and the oxidative e¡ect
of Cu2 ions. Lately, it was demonstrated that AmB con-
tained in Fungizone extracted cholesterol from LDL, thus
sensitizing them to oxidation [4]. This e¡ect would probably
represent the basic step to create a new red^ox equilibrium.
AmBisome, on the other hand, is not sensitive to oxidation,
does not bind to the LDL cholesterol and thus does not con-
tribute to the oxidation of the lipoprotein.
Aggregation represents one of the main characteristics of
strongly oxidized LDL [6,15,16]. Thus Fig. 3 presents the
kinetics of the oxidation of LDL induced by Fungizone (as
taken from Fig. 2) together with the variation of the light
scattering with time, as monitored by the absorbance at 680
nm. The great similarity between these two curves strongly
suggest that the aggregation of LDL is closely related to its
oxidation.
Fig. 3. The kinetics of LDL oxidation induced by AmB (as Fungi-
zone) as monitored by the changes in the absorbance at 234 nm (in
bold), together with the variation of the light scattering pattern (ab-
sorbance at 680 nm) as a function of time.
Fig. 4. The thermograms of native LDL (LDLn), and LDL mixed
with CuSO4 (LDL+Cu) or Fungizone (LDL+F). The transition
temperatures are indicated on each thermogram.
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In order to further investigate the e¡ect of Fungizone on
the lipid component of LDL, Fig. 4 illustrates the thermo-
grams recorded for native LDL, LDL in mixture with Fungi-
zone or with CuSO4. It shows the typical broad transitions
usually observed for LDL [17^19]. The results indicate that
the transition centered at 28.8‡C for native LDL is decreased
to 26.9‡C when Fungizone is used. On the other hand, it
increases to 30.0‡C when CuSO4 is used to oxidize LDL, in
good correlation with the literature data [18]. It is thus clear
that CuSO4 and Fungizone have di¡erent e¡ects: while
CuSO4 contributes to a certain rigidi¢cation of the lipid
components that are involved in the thermotropic transition
of LDL, to the contrary, Fungizone seems to £uidify these
lipid components. Thus, CuSO4 and Fungizone act di¡er-
ently towards the lipid part of LDL, thereby showing that
the structure of LDL is modi¢ed by two di¡erent mechan-
isms.
In conclusion, therefore, the results presented here have
shown that AmB as Fungizone, but not as AmBisome, is a
powerful oxidant of LDL, even more powerful than CuSO4,
itself considered as a strong oxidant of LDL. However, under
oxidizing conditions, a potentialization of the oxidation power
is observed, this e¡ect being much more important for AmBi-
some than for Fungizone. It is known that treatment with
AmB has severe, non-reversible, side e¡ects, such as nephro-
toxicity and cardiac complications [20,21]. Lately, a new study
[22] has demonstrated that AmB infusion in rats may induce
the formation of free radicals (lipid peroxides) in various or-
gans such as brain, lungs, and kidneys, increasing the lipid
peroxide level two, three, and almost four times, respectively.
In this context, the fact that AmB presents a great a⁄nity to
the lipid part of LDL, thus contributing to the oxidation of its
lipoprotein fraction, has important consequences that have to
be taken into account in the treatment of fungal infections,
particularly in the case of patients with cardiovascular or
kidney weaknesses.
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